Pathological upgrading and upstaging at radical prostatectomy in Jamaican men with low-risk prostate cancer

被引:2
|
作者
Morrison, Belinda F. [1 ]
Aikenb, William D. [1 ]
Reid, Gareth [1 ]
Mayhew, Richard [1 ]
Hanchard, Barrie [1 ]
机构
[1] Univ West Indies, Mona PO, Kingston 7, Jamaica
来源
ECANCERMEDICALSCIENCE | 2019年 / 13卷
关键词
low-risk prostate cancer; Jamaica; upgrading; upstaging; active surveillance; AFRICAN-AMERICAN MEN; ACTIVE SURVEILLANCE; BIOCHEMICAL OUTCOMES; SURGICAL MARGINS; BIOPSY; IMPACT; STRATIFICATION; MORTALITY; RACE;
D O I
10.3332/ecancer.2019.971
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Several studies suggest race-based health disparities in men with low-risk prostate cancer (PCa), with African American males having poorer oncological outcomes. We sought to determine the prevalence and predictors of pathological upgrading and upstaging in Jamaican men with low-risk PCa treated with radical prostatectomy (RP). Data on 141 men who met the National Comprehensive Cancer Network criteria for low-risk PCa and underwent RP at a single institution were reviewed. All men had a transrectal ultrasound-guided biopsy. Pre-operative clinical and final pathological data were obtained. Data were summarised as means and standard deviations or percentages as appropriate. Bivariate analyses such as independent samples t-tests and chi-square tables were conducted and logistic regression models were estimated to predict upgrading (>Gleason 6) and upstaging (p >= T3). The mean age was 59.5 +/- 7.8 years with mean prostate specific antigen (PSA) of 6.6 +/- 2 ng/mL. A total of 48.3% of men were upgraded and 11.4% were upstaged. Bivariate analyses indicated that PSA (p = 0.008) and percentage positive cores (p = 0.002) were associated with upgrading. PSA (p = 0.042) and percentage positive cores (p = 0.003) were significantly associated with upstaging. The odds of upgrading increased with increased PSA levels (OR 1.40, 95% CI 1.05-1.87, p = 0.021) or increased percentage positive cores (OR 8.27, 95% CI 2.19-31.16, p = 0.002). The odds of upstaging increased with increased PSA levels (OR 1.4, 95% CI 1.01-1.96, p = 0.046) and with increased percentages positive cores (OR 11.4; 95% CI 2.06-63.09, p = 0.005). Jamaican men with low-risk PCa are at high risk of pathological upgrading and upstaging at RP. These findings should be taken into consideration when discussing treatment options with these patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Racial Variation in Prostate Cancer Upgrading and Upstaging Among Men with Low-risk Clinical Characteristics
    Jalloh, Mohamed
    Myers, Frank
    Cowan, Janet E.
    Carroll, Peter R.
    Cooperberg, Matthew R.
    EUROPEAN UROLOGY, 2015, 67 (03) : 451 - 457
  • [2] Effects of pathological upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer
    Kovac, Evan
    Vertosick, Emily A.
    Sjoberg, Daniel D.
    Vickers, Andrew J.
    Stephenson, Andrew J.
    BJU INTERNATIONAL, 2018, 122 (06) : 1003 - 1009
  • [3] Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria
    Mitsuzuka, Koji
    Narita, Shintaro
    Koie, Takuya
    Kaiho, Yasuhiro
    Tsuchiya, Norihiko
    Yoneyama, Takahiro
    Kakoi, Narihiko
    Kawamura, Sadafumi
    Tochigi, Tatsuo
    Habuchi, Tomonori
    Ohyama, Chikara
    Arai, Yoichi
    BJU INTERNATIONAL, 2013, 111 (06) : 914 - 920
  • [4] Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients
    Flammia, Rocco S.
    Hoeh, Benedikt
    Hohenhorst, Lukas
    Sorce, Gabriele
    Chierigo, Francesco
    Panunzio, Andrea
    Tian, Zhe
    Saad, Fred
    Leonardo, Costantino
    Briganti, Alberto
    Antonelli, Alessandro
    Terrone, Carlo
    Shariat, Shahrokh F.
    Anceschi, Umberto
    Graefen, Markus
    Chun, Felix K. H.
    Montorsi, Francesco
    Gallucci, Michele
    Karakiewicz, Pierre, I
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (10) : 2521 - 2528
  • [5] Advancing Age and the Odds of Upgrading and Upstaging at Radical Prostatectomy in Men with Gleason Score 6 Prostate Cancer
    Leeman, Jonathan E.
    Chen, Ming-Hui
    Huland, Hartwig
    Graefen, Markus
    D'Amico, Anthony, V
    Tilki, Derya
    CLINICAL GENITOURINARY CANCER, 2019, 17 (06) : E1116 - E1121
  • [6] Upgrading and upstaging of low-risk prostate cancer among Korean patients: a multicenter study
    Hwang, Insang
    Lim, Donghoon
    Jeong, Young Beom
    Park, Seung Chol
    Noh, Jun Hwa
    Kwon, Dong Deuk
    Kang, Taek Won
    ASIAN JOURNAL OF ANDROLOGY, 2015, 17 (05) : 811 - 814
  • [7] Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy
    Gao, Yuan
    Jiang, Chen-Yi
    Mao, Shi-Kui
    Cui, Di
    Hao, Kui-Yuan
    Zhao, Wei
    Jiang, Qi
    Ruan, Yuan
    Xia, Shu-Jie
    Han, Bang-Min
    ASIAN JOURNAL OF ANDROLOGY, 2016, 18 (04) : 639 - 643
  • [8] Nomogram Predicting Adverse Pathology Outcome on Radical Prostatectomy in Low-Risk Prostate Cancer Men
    Nasri, Jordan
    Barthe, Flora
    Parekh, Sneha
    Ratnani, Parita
    Pedraza, Adriana M.
    Wagaskar, Vinayak G.
    Olivier, Jonathan
    Villers, Arnauld
    Tewari, Ash
    UROLOGY, 2022, 166 : 189 - 195
  • [9] Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients
    Rocco S. Flammia
    Benedikt Hoeh
    Lukas Hohenhorst
    Gabriele Sorce
    Francesco Chierigo
    Andrea Panunzio
    Zhe Tian
    Fred Saad
    Costantino Leonardo
    Alberto Briganti
    Alessandro Antonelli
    Carlo Terrone
    Shahrokh F. Shariat
    Umberto Anceschi
    Markus Graefen
    Felix K. H. Chun
    Francesco Montorsi
    Michele Gallucci
    Pierre I. Karakiewicz
    International Urology and Nephrology, 2022, 54 : 2521 - 2528
  • [10] Upgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy
    D'Elia, Carolina
    Cerruto, Maria Angela
    Cioffi, Antonio
    Novella, Giovanni
    Cavalleri, Stefano
    Artibani, Walter
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (06) : 1145 - 1149